Annual report
2342.TEDINET S100TPLD
Period2023-04-01 → 2024-03-31
Filed2024-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 146
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥11.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥12.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥89m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | −¥25m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥108m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥199m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥892m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥95m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥43m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥332m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥410m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥546m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥441m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥4m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | −¥440m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥9.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥10.4bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.8bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥5.0bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.4bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.5bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥392m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥21m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥281m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥216m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥982m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥48m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥319m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥343m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥485m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥667m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥0.24 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.32 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.52 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.45 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.38 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥109.31 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.45 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥355.19 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥356.98 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥388.43 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥283.07 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥254.29 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 60.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 0.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 32.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 236 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 236 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 213 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 248 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 250 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥371m | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥397m | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥365m | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥377m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥437m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥73m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥85m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥87m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥73m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥76m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥62m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥651m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥100m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥662m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥104m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥180m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥298m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥6.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥7.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.9bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥6.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥6.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-39.41 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.17 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥158.3 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.36 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.14 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥158 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.36 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥3 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥6 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥353.18 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥394.96 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥406.51 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥252.79 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥242.23 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 84.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 48.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 16,999,141 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,999,141 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 6 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 6 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 7 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 25 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 26 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 59
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥877,000 |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥7m |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥450,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥202m |
| Drug Discovery Support Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥254m |
| Drug Discovery Support Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥84m |
| Drug Discovery Support Businessreportable segment | employees | at 2024-03-31 | 161 pure |
| Drug Discovery Support Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.3bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.3bn |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2024-03-31 | ¥3.2bn |
| Drug Discovery Support Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥139m |
| Investments And Consulting Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥23m |
| Investments And Consulting Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥21m |
| Investments And Consulting Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.8bn |
| Investments And Consulting Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.8bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| Investments And Consulting Businessreportable segment | segment assets | at 2024-03-31 | ¥3.4bn |
| Investments And Consulting Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥430m |
| TGBS Businessreportable segment | employees | at 2024-03-31 | 69 pure |
| —segment total | employees | at 2024-03-31 | 230 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥277m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥105m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥13.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥13.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥7m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥291m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥559,000 |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥363,000 |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥4.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥210m |
| Drug Discovery Support Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥203m |
| Drug Discovery Support Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥106m |
| Drug Discovery Support Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.2bn |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2023-03-31 | ¥3.1bn |
| Drug Discovery Support Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥21m |
| Investments And Consulting Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥176m |
| Investments And Consulting Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥18m |
| Investments And Consulting Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.2bn |
| Investments And Consulting Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9.2bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1m |
| Investments And Consulting Businessreportable segment | segment assets | at 2023-03-31 | ¥3.3bn |
| Investments And Consulting Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥164m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥123m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥184m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,473
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for long term accounts payable other fin cf | CurrentYearDuration | -16135000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -78617000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -100906000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -83818000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | 484981000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -342689000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 1993000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 22726000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -1159074000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -993345000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4618521000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3459447000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3459447000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 2466101000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 16 | |
| Notes receivable trade | Prior1YearInstant | 41934000 | JPY |
| Notes receivable trade | CurrentYearInstant | 51351000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 1037823000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 1175339000 | JPY |
| Contract assets | Prior1YearInstant | 3698000 | JPY |
| Contract assets | CurrentYearInstant | 116043000 | JPY |
| Write downs of inventories | Prior1YearDuration | 163154000 | JPY |
| Write downs of inventories | CurrentYearDuration | -46527000 | JPY |
| Directors compensations sga | Prior1YearDuration | 208073000 | JPY |
| Directors compensations sga | CurrentYearDuration | 199551000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 471201000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 513794000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 57958000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 68556000 | JPY |
| Commission fee sga | Prior1YearDuration | 223138000 | JPY |
| Commission fee sga | CurrentYearDuration | 247637000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 37804000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 61338000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 2247161000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 9180572000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 11427734000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | 1950000 | JPY |
| Revenues from external customers | Prior1YearDuration | 11429684000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 1423000 | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 7423000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -7423000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 2253161000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 9181996000 | JPY |
| Net sales | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 11435158000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -5473000 | JPY |
| Net sales | Prior1YearDuration | 11429684000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 20659000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |